To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

Inclusion Criteria: 1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. 2. Male and Female subjects, between 18 and 65 years of , inclusive, at the time of signing informed consent. 3. Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales 3v, 4 and 5. Female subjects who meet Sinclair scales 2-4. Exclusion Criteria: 1. Subject with clinical diagnosis of non-AGA 2. Subject with clinically relevant abnormal skin or scalp findings which could interfere study assessment 3. Subject has used therapies associated with hair growth or may affect PRL levels, within defined time window before Screening 4. Subject with history of anterior pituitary, posterior pituitary, or hypothalamic dysfunction 5. Subject has clinically significantly abnormal laboratory tests at Screening 6. Known hypersensitivity to any of the IMP ingredients 7. Any other conditions in the investigator's opinion that prevent the subject from participating